

New Approaches in Atherothrombosis

Bibliography of One Hundred Key Papers

selected by **Jan Steffel, MD** and **Thomas F. Lüscher, MD, FRCP**

*Cardiology - Cardiovascular Center - University Hospital Zurich and Cardiovascular Research
Institute of Physiology - University of Zurich-Irchel - SWITZERLAND*

Altwegg LA, Neidhart M, Hersberger M, et al.

Myeloid-related protein 8/14 complex is released by monocytes and granulocytes at the site of coronary occlusion: a novel, early, and sensitive marker of acute coronary syndromes.

Eur Heart J. 2007;28:941-948.

Anderson TJ, Elstein E, Haber H, Charbonneau F.

Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease (BANFF study).

J Am Coll Cardiol. 2000;35:60-66.

Awata M, Kotani J, Uematsu M, et al.

Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents.

Circulation. 2007;116:910-916.

Barton M, Haudenschild CC, d'Uscio LV, Shaw S, Munter K, Lüscher TF.

Endothelin ET_A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Proc Natl Acad Sci U S A. 1998;95:14367-14372.

Bavendiek U, Libby P, Kilbride M, Reynolds R, Mackman N, Schonbeck U.

Induction of tissue factor expression in human endothelial cells by CD40 ligand is mediated via activator protein 1, nuclear factor kappa B, and Egr-1.

J Biol Chem. 2002;277:25032-25039.

Belhassen L, Pelle G, Dubois-Rande JL, et al.

Improved endothelial function by the thromboxane A₂ receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin.

J Am Coll Cardiol. 2003;41:1198-1204.

**Bots ML, Remme WJ, Lüscher TF, et al:
EUROPA-PERFECT Investigators.**

ACE inhibition and endothelial function: main findings of PERFECT, a sub-study of the EUROPA trial.

Cardiovasc Drugs Ther. 2007;21:269-279.

Bragulat E, Larrousse M, Coca A, de la Sierra A.

Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients.

Br J Biomed Sci. 2003;60:191-196.

Brunner H, Cockcroft JR, Deanfield J, et al.

Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension.

J Hypertens. 2005;23:233-246.

Bibliography of One Hundred Key Papers

- Camera M, Giesen PL, Fallon J, et al.** Cooperation between VEGF and TNF-alpha is necessary for exposure of active tissue factor on the surface of human endothelial cells. *Arterioscler Thromb Vasc Biol.* 1999;19:531-537.
-
- Carmeliet P, Mackman N, Moons L, et al.** Role of tissue factor in embryonic blood vessel development. *Nature.* 1996;383:73-75.
-
- Ceconi C, Fox KM, Remme WJ, et al; EUROPA Investigators.** ACE inhibition with Perindopril and endothelial function. Results of a substudy of the EUROPA study: PERTINENT. *Cardiovasc Res.* 2007;73:237-246.
-
- Cirillo P, Cali G, Golino P, et al.** Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. *Circulation.* 2004;109:2911-2916.
-
- Coughlin SR.** How the protease thrombin talks to cells. *Proc Natl Acad Sci U S A.* 1999;96:11023-11027.
-
- Crouch MA, Nappi JM, Cheang KI.** Glycoprotein IIb/IIIa receptor inhibitors in percutaneous coronary intervention and acute coronary syndrome. *Ann Pharmacother.* 2003;37:860-875.
-
- Cyrus T, Yao Y, Ding T, et al.** A novel thromboxane receptor antagonist and synthase inhibitor, BM-573, reduces development and progression of atherosclerosis in LDL receptor deficient mice. *Eur J Pharmacol.* 2007;561:105-111.
-
- Dogne JM, Hanson J, Pratico D.** Thromboxane, prostacyclin and isoprostanes: therapeutic targets in atherogenesis. *Trends Pharmacol Sci.* 2005;26:639-644.
-
- Drake TA, Hannani K, Fei HH, Lavi S, Berliner JA.** Minimally oxidized low-density lipoprotein induces tissue factor expression in cultured human endothelial cells. *Am J Pathol.* 1991;138:601-607.
-
- Dupuis J, Tardif JC, Cernacek P, Theroux P.** Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes. The RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial. *Circulation.* 1999;99:3227-3233.
-
- Eto M, Kozai T, Cosentino F, Joch H, Lüscher TF.** Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways. *Circulation.* 2002;105:1756-1759.
-
- Eto M, Rathgeb L, Cosentino F, Kozai T, Lüscher TF.** Statins blunt thrombin-induced down-regulation of endothelial nitric oxide synthase expression in human endothelial cells. *J Cardiovasc Pharmacol.* 2006;47:663-667.
-
- Fischman DL, Leon MB, Baim DS, et al.** A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. *N Engl J Med.* 1994;331:496-501.
-
- FitzGerald GA, Austin S, Egan K, et al.** Cyclo-oxygenase products and atherothrombosis. *Ann Med.* 2000;32(suppl 1):21-26.
-



-
- Fox KM; EUROpean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators.** *Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease; randomized, double-blind, placebo-controlled, multicenter trial (the EUROPA study).* **Lancet.** 2003;362:782-788.
-
- Furchgott RF, Zawadzki JV.** *The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine.* **Nature.** 1980;288:373-376.
-
- Gachet C.** *Regulation of platelet functions by P2 receptors.* **Annu Rev Pharmacol Toxicol.** 2006;46:277-300.
-
- Gawaz M, Langer H, May AE.** *Platelets in inflammation and atherogenesis.* **J Clin Invest.** 2005;115:3378-3384.
-
- Ghiadoni L, Taddei S, Virdis A, et al.** *Endothelial function and common carotid artery wall thickening in patients with essential hypertension.* **Hypertension.** 1998;32:25-32.
-
- Ghiadoni L, Virdis A, Magagna A, Taddei S, Salvetti A.** *Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension.* **Hypertension.** 2000;35:501-506.
-
- Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, et al.** *First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARCI779 in healthy volunteers.* **Circulation.** 2007;116:2678-2686.
-
- Giugliano RP, Wiviott SD, Stone PH, et al.** *Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.* **J Am Coll Cardiol.** 2007;49:2398-2407.
-
- Hansson GK.** *Inflammation, atherosclerosis, and coronary artery disease.* **N Engl J Med.** 2005;352:1685-1695.
-
- Hechler B, Leon C, Vial C, et al.** *The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.* **Blood.** 1998;92:152-159.
-
- Hechler B, Nonne C, Roh EJ, et al.** *MRS2500 [2-iodo-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphate], a potent, selective, and stable antagonist of the platelet P2Y1 receptor with strong antithrombotic activity in mice.* **J Pharmacol Exp Ther.** 2006;316:556-563.
-
- Herkert O, Diebold I, Brandes RP, Hess J, Busse R, Gorchach A.** *NADPH oxidase mediates tissue factor-dependent surface procoagulant activity by thrombin in human vascular smooth muscle cells.* **Circulation.** 2002;105:2030-2036.
-
- Hollopeter G, Jantzen HM, Vincent D, et al.** *Identification of the platelet ADP receptor targeted by antithrombotic drugs.* **Nature.** 2001;409:202-207.
-
- Horlitz M, Sigwart U, Niebauer J.** *Fighting restenosis after coronary angioplasty: contemporary and future treatment options.* **Int J Cardiol.** 2002;83:199-205.
-

Bibliography of One Hundred Key Papers

- John S, Schlaich M, Langenfeld M, et al.** *Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study.*
Circulation. 1998;98:211-216.
-
- Joner M, Finn AV, Farb A, et al.** *Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.*
J Am Coll Cardiol. 2006;48:193-202.
-
- Kato Y, Kita Y, Hirasawa-Taniyama Y, et al.** *Inhibition of arterial thrombosis by a protease-activated receptor 1 antagonist, FR171113, in the guinea pig.*
Eur J Pharmacol. 2003;473:163-169.
-
- Katusic ZS, Vanhoutte PM.** *Superoxide anion is an endothelium-derived contracting factor.*
Am J Physiol. 1989;257:H33-H37.
-
- Kawano H, Tsuji H, Nishimura H, et al.** *Serotonin induces the expression of tissue factor and plasminogen activator inhibitor-1 in cultured rat aortic endothelial cells.*
Blood. 2001;97:1697-1702.
-
- Keeley EC, Boura JA, Grines CL.** *Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.*
Lancet. 2003;361:13-20.
-
- Laufs U, La Fata V, Plutzky J, Liao JK.** *Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors.*
Circulation. 1998;97:1129-1135.
-
- Léon C, Alex M, Klocke A, et al.** *Platelet ADP receptors contribute to the initiation of intravascular coagulation.*
Blood. 2004;103:594-600.
-
- Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC.** *Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis.*
N Engl J Med. 1991;325:997-1001.
-
- Lichtlen PR, Hugenholtz PG, Rafflenbeul W, Hecker H, Jost S, Deckers JW.** *Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators.*
Lancet. 1990;335:1109-1113.
-
- Liuzzo G, Biasucci LM, Gallimore JR, et al.** *The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina.*
N Engl J Med. 1994;331:417-424.
-
- Llorente-Cortes V, Otero-Vinas M, Camino-Lopez S, Llampayas O, Badimon L.** *Aggregated low-density lipoprotein uptake induces membrane tissue factor procoagulant activity and microparticle release in human vascular smooth muscle cells.*
Circulation. 2004;110:452-459.
-
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group.** *Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels.*
N Engl J Med. 1998;339:1349-1357.
-



-
- Lüscher TF, Noll G.** *Endothelial function as an end-point in interventional trials: concepts, methods and current data.*
J Hypertens Suppl. 1996;14:S111-S119.
-
- Lüscher TF, Steffel J, Eberli FR, et al.** *Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications.*
Circulation. 2007;115:1051-1058.
-
- Mackman N.** *Regulation of the tissue factor gene.*
Thromb Haemost. 1997;78:747-754.
-
- Maier W, Altwegg LA, Corti R, et al.** *Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein.*
Circulation. 2005;111:1355-1361.
-
- Mallat Z, Benamer H, Hugel B, et al.** *Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes.*
Circulation. 2000;101:841-843.
-
- Mancini GB, Henry GC, Macaya C, et al.** *Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study.*
Circulation. 1996;94:258-265.
-
- Mechtcheriakova D, Schabbauer G, Lucerna M, et al.** *Specificity, diversity, and convergence in VEGF and TNF-alpha signaling events leading to tissue factor up-regulation via EGR-1 in endothelial cells.*
FASEB J. 2001;15:230-242.
-
- Monton M, Jimenez A, Nunez A, et al.** *Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.*
J Cardiovasc Pharmacol. 2000;35:906-913.
-
- Morice MC, Serruys PW, Sousa JE, et al.** *A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.*
N Engl J Med. 2002;346:1773-1780.
-
- Moses JW, Leon MB, Popma JJ, et al.** *Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.*
N Engl J Med. 2003;349:1315-1323.
-
- Napoleone E, Di Santo A, Lorenzet R.** *Monocytes upregulate endothelial cell expression of tissue factor: a role for cell-cell contact and cross-talk.*
Blood. 1997;89:541-549.
-
- Nieswandt B, Watson SP.** *Platelet-collagen interaction: is GPVI the central receptor?*
Blood. 2003;102:449-461.
-
- Nonne C, Lenain N, Hechler B, et al.** *Importance of platelet phospholipase C_γ2 signaling in arterial thrombosis as a function of lesion severity.*
Arterioscler Thromb Vasc Biol. 2005;25:1293-1298.
-

Bibliography of One Hundred Key Papers

- Oemar BS, Tschudi MR, Godoy N, Brovkovich V, Malinski T, Lüscher TF.** *Reduced endothelial nitric oxide synthase expression and production in human atherosclerosis.* **Circulation.** 1998;97:2494-2498.
-
- Palmer RM, Ashton DS, Moncada S.** *Vascular endothelial cells synthesize nitric oxide from L-arginine.* **Nature.** 1988;333:664-666.
-
- Podrez EA, Byzova TV, Febbraio M, et al.** *Platelet CD36 links hyperlipidemia, oxidant stress and a prothrombotic phenotype.* **Nat Med.** 2007;13:1086-1095.
-
- Rader DJ.** *Illuminating HDL—is it still a viable therapeutic target?* **N Engl J Med.** 2007;357:2180-2183.
-
- Rolin S, Hanson J, Vastersaegher C, et al.** *BM-520, an original TXA₂ modulator, inhibits the action of thromboxane A₂ and 8-iso-prostaglandin F₂alpha in vitro and in vivo on human and rodent platelets, and aortic vascular smooth muscles from rodents.* **Prostaglandins Other Lipid Mediat.** 2007;84:14-23.
-
- Rubanyi GM, Vanhoutte PM.** *Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor.* **Am J Physiol.** 1986;250:H822-H827.
-
- Ruggeri ZM.** *Platelets in atherothrombosis.* **Nat Med.** 2002;8:1227-1234.
-
- Sanz J, Moreno PR, Fuster V.** *Update on advances in atherothrombosis.* **Nat Clin Pract Cardiovasc Med.** 2007;4:78-89.
-
- Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A.** *Tissue factor induces migration of cultured aortic smooth muscle cells.* **Thromb Haemost.** 1996;75:389-392.
-
- Schechter AD, Giesen PL, Taby O, et al.** *Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation.* **J Clin Invest.** 1997;100:2276-2285.
-
- Schieffer B, Bunte C, Witte J, et al.** *Comparative effects of AT₁-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease.* **J Am Coll Cardiol.** 2004;44:362-368.
-
- Schorr K, Huber K.** *Prasugrel, a new thienopyridine.* **Haemostaseologie.** 2007;27:351-355.
-
- Serruys PW, de Jaegere P, Kiemeneij F, et al.** *A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease.* **N Engl J Med.** 1994;331:489-495.
-
- Shepherd J, Cobbe SM, Ford I, et al.** *Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group.* **N Engl J Med.** 1995;333:1301-1307.
-
- Smith EJ, Jain AK, Rothman MT.** *New developments in coronary stent technology.* **J Interv Cardiol.** 2006;19:493-499.
-



- Spieker L, Ruschitzka F, Lüscher TF, Noll G.** *HDL-Cholesterin bei Atherosklerose—zu wenig des Guten [HDL-cholesterol in atherosclerosis—too little of a good thing].* **Schweiz Med Forum.** 2003;39:920-926.
-
- Spieker LE, Sudano I, Hurlimann D, et al.** *High-density lipoprotein restores endothelial function in hypercholesterolemic men.* **Circulation.** 2002;105:1399-1402.
-
- Stamler JS, Singel DJ, Loscalzo J.** *Biochemistry of nitric oxide and its redox-activated forms.* **Science.** 1992;258:1898-1902.
-
- Steffel J, Akhmedov A, Greutert H, Lüscher TF, Tanner FC.** *Histamine induces tissue factor expression: implications for acute coronary syndromes.* **Circulation.** 2005;112:341-349.
-
- Steffel J, Hermann M, Greutert H, et al.** *Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH₂ kinase phosphorylation.* **Circulation.** 2005;111:1685-1689.
-
- Steffel J, Lüscher TF, Tanner FC.** *Tissue factor in cardiovascular diseases: molecular mechanisms and clinical implications.* **Circulation.** 2006;113:722-731.
-
- Steinhubl SR, Badimon JJ, Bhatt DL, et al.** *Clinical evidence for anti-inflammatory effects of antiplatelet therapy in patients with atherothrombotic disease.* **Vasc Med.** 2007;12:113-122.
-
- Sudano I, Spieker LE, Hermann F, et al.** *Protection of endothelial function: targets for nutritional and pharmacological interventions.* **J Cardiovasc Pharmacol.** 2006;47(suppl 2):S136-S150; discussion S172-136.
-
- Taddei S, Virdis A, Ghiadoni L, Uleri S, Magagna A, Salvetti A.** *Lacidipine restores endothelium-dependent vasodilation in essential hypertensive patients.* **Hypertension.** 1997;30:1606-1612.
-
- Tanner F, Boulanger C, Lüscher T.** *Endothelium-derived nitric oxide, endothelin and platelet vessel wall interaction: alterations in hypercholesterolemia and atherosclerosis.* **Semin Thromb Hemost.** 1993;19:167-175.
-
- Thiruvikraman SV, Guha A, Roboz J, Taubman MB, Nemerson Y, Fallon JT.** *In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X.* **Lab Invest.** 1996;75:451-461.
-
- van Boven AJ, Jukema JW, Zwinderman AH, Crijns HJ, Lie KI, Bruschke AV; REGRESS Study Group.** *Reduction of transient myocardial ischemia with pravastatin in addition to the conventional treatment in patients with angina pectoris.* **Circulation.** 1996;94:1503-1505.
-
- Vanhoelbeke K, Ulrichs H, Van de Walle G, et al.** *Inhibition of platelet glycoprotein Ib and its antithrombotic potential.* **Curr Pharm Des.** 2007;13:2684-2697.
-
- Verhaar MC, Honing ML, van Dam T, et al.** *Nifedipine improves endothelial function in hypercholesterolemia, independently of an effect on blood pressure or plasma lipids.* **Cardiovasc Res.** 1999;42:752-760.

Bibliography of One Hundred Key Papers

- Wihlborg AK, Wang L, Braun OO, et al.** *ADP receptor P2Y₁₂ is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels.* **Arterioscler Thromb Vasc Biol.** 2004;24:1810-1815.
-
- Wilcox JN, Smith KM, Schwartz SM, Gordon D.** *Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque.* **Proc Natl Acad Sci U S A.** 1989;86:2839-2843.
-
- Wiviott SD, Braunwald E, McCabe CH, et al.** *Prasugrel versus clopidogrel in patients with acute coronary syndromes.* **N Engl J Med.** 2007;357:2001-2015.
-
- Wiviott SD, de Lemos JA.** *Antiplatelet agents make a comeback in ST-elevation myocardial infarction.* **Am Heart J.** 2007;154:603-606.
-
- Wolberg AS, Monroe DM, Roberts HR, Hoffman MR.** *Tissue factor de-encryption: ionophore treatment induces changes in tissue factor activity by phosphatidylserine-dependent and -independent mechanisms.* **Blood Coagul Fibrinolysis.** 1999;10:201-210.
-
- Xuereb JM, Sie P, Boneu B, Constans J.** *Up-regulation of tissue factor expression by platelet-derived growth factor in human vascular smooth muscle cells in culture—role of mitogen-activated protein kinase and effects of intracellular cyclic AMP.* **Thromb Haemost.** 1997;78:1520-1526.
-
- Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK.** *Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.* **N Engl J Med.** 2001;345:494-502.
-
- Zuccollo A, Shi C, Mastroianni R, et al.** *The thromboxane A₂ receptor antagonist S18886 prevents enhanced atherogenesis caused by diabetes mellitus.* **Circulation.** 2005;112:3001-3008.
-